Advanced search
1 file | 1.58 MB Add to list

Model-based analysis of treatment effects of paclitaxel microspheres in a microscopic peritoneal carcinomatosis model in mice.

Feifan Xie (UGent) , Kaat De Clercq (UGent) , Chris Vervaet (UGent) , Jan Van Bocxlaer (UGent) , Pieter Colin (UGent) and An Vermeulen (UGent)
Author
Organization
Abstract
Purpose: Paclitaxel (PTX)-loaded genipin-crosslinked gelatin microspheres (GP-MS) are a prolonged IP delivery system under development for the treatment of peritoneal minimal residual disease (pMRD). Here, we show the use of a pharmacokinetic-pharmacodynamic (PKPD) modelling approach to inform the formulation development of PTX-GP-MS in a mice pMRD model. Methods: PTX blood concentrations and survival data were obtained in Balb/c Nu mice receiving different single IP doses (7.5 and/or 35 mg/kg) of PTX-ethanolic loaded GP-MS (PTXEtOH-GP-MS), PTX-nanosuspension loaded GP-MS (PTXnano-GP-MS), and immediate release formulation Abraxane (R). A population PK model was developed to characterize the PTX blood concentration pattern and to predict PTX concentrations in peritoneum. Afterwards, PKPD relationships between the predicted peritoneal or blood concentrations and survival were explored using time-to-event modelling. Results: A PKPD model was developed that simultaneously describes the competing effects of treatment efficacy (driven by peritoneal concentration) and toxicity (driven by blood concentration) of PTX on survival. Clear survival advantages of PTXnano-GP-MS over PTXEtOH-GP-MS and Abraxane (R) were found. Simulations of different doses of PTXnano-GP-MS demonstrated that drug-induced toxicity is high at doses between 20 and 35 mg/kg. Conclusions: The model predicts that the dose range of 7.5-15 mg/kg of PTXnano-GP-MS provides an optimal balance between efficacy and safety.
Keywords
Mouse, NONMEM, Paclitaxel, Peritoneal, PKPD, HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY, GYNECOLOGIC-ONCOLOGY-GROUP, OVARIAN-CANCER, STAGE-III, IN-VITRO, CYTOREDUCTIVE SURGERY, CISPLATIN, VIVO, RATIONALE, STANDARD

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.58 MB

Citation

Please use this url to cite or link to this publication:

MLA
Xie, Feifan, et al. “Model-Based Analysis of Treatment Effects of Paclitaxel Microspheres in a Microscopic Peritoneal Carcinomatosis Model in Mice.” PHARMACEUTICAL RESEARCH, vol. 36, no. 9, 2019.
APA
Xie, F., De Clercq, K., Vervaet, C., Van Bocxlaer, J., Colin, P., & Vermeulen, A. (2019). Model-based analysis of treatment effects of paclitaxel microspheres in a microscopic peritoneal carcinomatosis model in mice. PHARMACEUTICAL RESEARCH, 36(9).
Chicago author-date
Xie, Feifan, Kaat De Clercq, Chris Vervaet, Jan Van Bocxlaer, Pieter Colin, and An Vermeulen. 2019. “Model-Based Analysis of Treatment Effects of Paclitaxel Microspheres in a Microscopic Peritoneal Carcinomatosis Model in Mice.” PHARMACEUTICAL RESEARCH 36 (9).
Chicago author-date (all authors)
Xie, Feifan, Kaat De Clercq, Chris Vervaet, Jan Van Bocxlaer, Pieter Colin, and An Vermeulen. 2019. “Model-Based Analysis of Treatment Effects of Paclitaxel Microspheres in a Microscopic Peritoneal Carcinomatosis Model in Mice.” PHARMACEUTICAL RESEARCH 36 (9).
Vancouver
1.
Xie F, De Clercq K, Vervaet C, Van Bocxlaer J, Colin P, Vermeulen A. Model-based analysis of treatment effects of paclitaxel microspheres in a microscopic peritoneal carcinomatosis model in mice. PHARMACEUTICAL RESEARCH. 2019;36(9).
IEEE
[1]
F. Xie, K. De Clercq, C. Vervaet, J. Van Bocxlaer, P. Colin, and A. Vermeulen, “Model-based analysis of treatment effects of paclitaxel microspheres in a microscopic peritoneal carcinomatosis model in mice.,” PHARMACEUTICAL RESEARCH, vol. 36, no. 9, 2019.
@article{8621116,
  abstract     = {Purpose: Paclitaxel (PTX)-loaded genipin-crosslinked gelatin microspheres (GP-MS) are a prolonged IP delivery system under development for the treatment of peritoneal minimal residual disease (pMRD). Here, we show the use of a pharmacokinetic-pharmacodynamic (PKPD) modelling approach to inform the formulation development of PTX-GP-MS in a mice pMRD model.
Methods: PTX blood concentrations and survival data were obtained in Balb/c Nu mice receiving different single IP doses (7.5 and/or 35 mg/kg) of PTX-ethanolic loaded GP-MS (PTXEtOH-GP-MS), PTX-nanosuspension loaded GP-MS (PTXnano-GP-MS), and immediate release formulation Abraxane (R). A population PK model was developed to characterize the PTX blood concentration pattern and to predict PTX concentrations in peritoneum. Afterwards, PKPD relationships between the predicted peritoneal or blood concentrations and survival were explored using time-to-event modelling.
Results: A PKPD model was developed that simultaneously describes the competing effects of treatment efficacy (driven by peritoneal concentration) and toxicity (driven by blood concentration) of PTX on survival. Clear survival advantages of PTXnano-GP-MS over PTXEtOH-GP-MS and Abraxane (R) were found. Simulations of different doses of PTXnano-GP-MS demonstrated that drug-induced toxicity is high at doses between 20 and 35 mg/kg.
Conclusions: The model predicts that the dose range of 7.5-15 mg/kg of PTXnano-GP-MS provides an optimal balance between efficacy and safety.},
  articleno    = {127},
  author       = {Xie, Feifan and De Clercq, Kaat and Vervaet, Chris and Van Bocxlaer, Jan and Colin, Pieter and Vermeulen, An},
  issn         = {0724-8741},
  journal      = {PHARMACEUTICAL RESEARCH},
  keywords     = {Mouse,NONMEM,Paclitaxel,Peritoneal,PKPD,HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY,GYNECOLOGIC-ONCOLOGY-GROUP,OVARIAN-CANCER,STAGE-III,IN-VITRO,CYTOREDUCTIVE SURGERY,CISPLATIN,VIVO,RATIONALE,STANDARD},
  language     = {eng},
  number       = {9},
  pages        = {13},
  title        = {Model-based analysis of treatment effects of paclitaxel microspheres in a microscopic peritoneal carcinomatosis model in mice.},
  url          = {http://dx.doi.org/10.1007/s11095-019-2660-1},
  volume       = {36},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: